MetaCap

Establishment Labs Holdings Inc. (ESTA)

NASDAQ: ESTAHealth CareIndustrial SpecialtiesUSD

69.14-0.47 (-0.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ESTA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.27
52-week range
53.16 – 97.59
Day range
65.00 – 71.07
Volume / Avg
464.24K / 411.24K
Beta
—

52-week range

$53.16$97.59

ESTA stock today

Shares of Establishment Labs (ESTA) finished lower on Nov 20 at $69.14, a drop of 0.68% or $0.47 per share, versus the S&P 500's 3.70% decline. Shares are 29.2% below their 52-week high of $97.59, set on Aug 3, 2026 and 30.1% above the 52-week low of $53.16, in the middle of the past year's range. ESTA is down 5.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.6%.

Establishment Labs has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Establishment Labs

Company profile

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders.

Industry
Industrial Specialties
CEO
Mr. Fillipo Peter Caldini
Headquarters
Austin, TX
Employees
1,004
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Establishment Labs generated $211.1 million in revenue, up 27.1% from fiscal 2024, its 5th consecutive year of revenue growth. Establishment Labs reported a net loss of $51.1 million, compared with a loss of $84.6 million a year earlier. Gross margin was 69.3% (up from 66.0%) and operating margin -18.5%.

Establishment Labs annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$211.08M$166.03M$165.15M$161.70M$126.68M
Growth+27.14%+0.53%+2.13%+27.64%+49.61%
Net income$-51.06M$-84.60M$-78.50M$-75.21M$-41.14M
EPS (diluted)$-1.72$-3.00$-3.07$-3.08$-1.72

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$98.00+41.74%

  • Strong buy 2
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $90.00High $105.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.38 vs $-0.27
Surprise
-40.74%

ESTA news

All ESTA news

Establishment Labs peers

Health Care sector
ESTA peer companies
CompanyPrice% ChgMarket capCompare
DSGRDistribution Solutions Group Inc.35.00-0.09%$1.62Bvs ESTA
ENOVEnovis Corporation25.47-2.90%$1.47Bvs ESTA
TRSTriMas Corporation36.77-2.52%$1.30Bvs ESTA
CDRECadre Holdings Inc.29.45-3.63%$1.26Bvs ESTA
XPELXPEL Inc.38.12+1.36%$1.05Bvs ESTA
FOILLondian Wason New Energy Tech Inc. ADR12.30-11.95%$969.05Mvs ESTA
WLFCWillis Lease Finance Corporation41.96-2.31%$957.23Mvs ESTA
ADSEADS-TEC ENERGY PLC9.78+3.82%$735.32Mvs ESTA

Indexes, lists and sector

Establishment Labs stock FAQ

What is Establishment Labs's stock price today?

ESTA last traded at $69.14 as of Nov 20, 4:00 PM EST, down 0.68% on the day. Prices are delayed at least 15 minutes.

Who is Establishment Labs's CEO?

Mr. Fillipo Peter Caldini is the chief executive officer of Establishment Labs Holdings Inc., which has about 1,004 employees.

What is the ESTA 52-week high?

The 52-week high for ESTA is $97.59 and the 52-week low is $53.16. The stock is currently 29.2% below its high.

Compare ESTA